Jane Street Group LLC raised its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 37.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 90,334 shares of the company's stock after buying an additional 24,684 shares during the quarter. Jane Street Group LLC owned about 0.20% of Avanos Medical worth $1,438,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Quantbot Technologies LP bought a new position in Avanos Medical during the fourth quarter valued at about $64,000. Tower Research Capital LLC TRC grew its holdings in shares of Avanos Medical by 493.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company's stock worth $129,000 after purchasing an additional 6,714 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Avanos Medical during the fourth quarter valued at approximately $162,000. Mariner LLC raised its stake in shares of Avanos Medical by 18.0% in the fourth quarter. Mariner LLC now owns 10,655 shares of the company's stock valued at $170,000 after purchasing an additional 1,625 shares in the last quarter. Finally, US Bancorp DE raised its stake in shares of Avanos Medical by 18.0% in the fourth quarter. US Bancorp DE now owns 14,093 shares of the company's stock valued at $224,000 after purchasing an additional 2,147 shares in the last quarter. 95.17% of the stock is owned by institutional investors.
Analyst Ratings Changes
Separately, Wall Street Zen upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.
Check Out Our Latest Research Report on AVNS
Insider Buying and Selling
In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total value of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares in the company, valued at $1,251,216.75. This represents a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.64% of the stock is owned by corporate insiders.
Avanos Medical Price Performance
Shares of NYSE:AVNS traded down $0.17 during midday trading on Friday, reaching $12.32. 361,531 shares of the company's stock were exchanged, compared to its average volume of 361,271. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The company's 50 day simple moving average is $13.01 and its two-hundred day simple moving average is $15.45. Avanos Medical, Inc. has a 12 month low of $11.84 and a 12 month high of $25.36. The firm has a market capitalization of $569.49 million, a PE ratio of 36.22 and a beta of 1.13.
Avanos Medical (NYSE:AVNS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.07. The firm had revenue of $167.50 million during the quarter, compared to analysts' expectations of $161.75 million. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The company's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the company earned $0.22 earnings per share. Equities research analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.
Avanos Medical Profile
(
Free Report)
Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.
Featured Articles
Before you consider Avanos Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avanos Medical wasn't on the list.
While Avanos Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
